Latest Close
$1.13
News
ACXP
Acurx Pharmaceuticals, Inc. News
This news view pulls recent coverage and headlines tied to ACXP.
1y Change
-$5.38 (-82.57%)
Market Cap
$6,309,924.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
none
From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television
ACCESS Newswire • Oct 24, 2026
Read articleAcurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
PR Newswire • Oct 21, 2026
Read articleAcurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
ACCESS Newswire • Oct 5, 2026
Read articleAcurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
PR Newswire • Sep 29, 2026
Read articleNew to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
ACCESS Newswire • Sep 19, 2026
Read articleAcurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
PR Newswire • Sep 14, 2026
Read article